Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Diagnosis of breast carcinoma with HER-2 overexpression~* At least one measurable brain metastasis~* Patients for whom, according to investigator assessment, whole brain radiotherapy is the best therapeutic option~* Performance status (WHO) \</=2~* Life expectancy \>/=3 months~Exclusion Criteria:~* Presence of neoplastic meningitis~* Any prior radiotherapy to the brain~* Patients for whom, according to investigator assessment, stereotactic radiotherapy is the best therapeutic option~* Previous neoplasms, other than breast carcinoma, within 5 years since enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Monotherapy (Type: EXPERIMENTAL): Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).